Document Detail

Treatment of hepatitis C virus carriers with persistently normal alanine aminotransferase levels with peginterferon alpha-2a and ribavirin: a multicentric study.
MedLine Citation:
PMID:  19422478     Owner:  NLM     Status:  MEDLINE    
BACKGROUND/AIMS: To evaluate, in clinical practice, the efficacy and safety of combined antiviral treatment in hepatitis C virus (HCV) carriers with normal alanine aminotransferase (ALT) levels. METHODS: Eighty-eight HCV carriers with persistently normal ALT levels were enrolled. All patients received peginterferon (PEG-IFN) alpha-2a 180 microg once weekly plus ribavirin (RBV) 800 mg/day for 24 weeks (HCV-2 and -3) or 1000-1200 mg/day for 48 weeks (HCV-1). RESULTS: Rapid virological response (RVR) was seen in 66/88 patients (75%): 19/32 HCV-1 (59%), 40/46 HCV-2 (87%) and 7/10 HCV-3 patients. Younger patients, leaner subjects and patients with non-1 genotype or lower baseline HCV RNA levels were more likely to achieve an RVR. Sustained virological response (SVR) was seen in 69/88 patients (78%): 20/32 HCV-1 patients (62%), 41/46 HCV-2 patients (89%) and 8/10 (80%) HCV-3 patients. The overall SVR rate was 88% in patients with RVR (58/66) and 50% in those without RVR. CONCLUSIONS: The combination of PEG-IFN alpha-2a and RBV produces, in patients with normal ALT, virological response rates that are comparable or even higher than those obtained in patients with elevated ALT levels. Thus, we suggest that in selected cases immediate therapy might be preferred to a 'wait-and-see' policy.
Claudio Puoti; Adriano M Pellicelli; Mario Romano; Fabrizio Mecenate; Riccardo Guarisco; Giorgio Barbarini; Ettore Mazzoni; Lucia Spilabotti; Lia Bellis; Federica Paglia; Angelo Barlattani; Antonio Picardi; Amerigo Paffetti; Maria Elena Bonaventura; Lorenzo Nosotti; Olga Mitidieri; Orlando Dell'Unto; Roberto Villani; Chiara Dell'Unto; Aldo Morrone; Fabrizio Soccorsi;
Related Documents :
19273538 - Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cu...
9798778 - Mesenchymal hamartoma of the liver.
12220308 - Emerging indications for mars dialysis.
7547538 - Ucla liver transplantation: analysis of the first 1,000 patients.
17606558 - A decline in the frequency of neonatal exchange transfusions and its effect on exchange...
7955378 - Is carbohydrate-deficient transferrin in serum useful for detecting excessive alcohol c...
Publication Detail:
Type:  Journal Article; Multicenter Study     Date:  2009-04-28
Journal Detail:
Title:  Liver international : official journal of the International Association for the Study of the Liver     Volume:  29     ISSN:  1478-3231     ISO Abbreviation:  Liver Int.     Publication Date:  2009 Nov 
Date Detail:
Created Date:  2009-10-08     Completed Date:  2010-01-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160857     Medline TA:  Liver Int     Country:  England    
Other Details:
Languages:  eng     Pagination:  1479-84     Citation Subset:  IM    
Department of Internal Medicine and Liver Unit, Marino Hospital, Rome, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alanine Transaminase / blood*
Antiviral Agents / administration & dosage*
Carrier State / drug therapy*,  pathology,  virology
Drug Therapy, Combination
Hepatitis C / drug therapy*,  pathology,  virology
Interferon Alfa-2a / administration & dosage*
Liver / pathology
Middle Aged
Polyethylene Glycols / administration & dosage*
RNA, Viral / blood
Ribavirin / administration & dosage*
Reg. No./Substance:
0/Antiviral Agents; 0/Polyethylene Glycols; 0/RNA, Viral; 0/peginterferon alfa-2a; 36791-04-5/Ribavirin; 76543-88-9/Interferon Alfa-2a; EC Transaminase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Diabetes pattern on the 75 g oral glucose tolerance test is a risk factor for hepatocellular carcino...
Next Document:  Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patient...